… in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted
Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13: …

… Minimal residual disease measurement during or … patients to identify those most likely to
benefit from escalated or additional therapy For patients in complete remission minimal disease …

… Next-generation sequencing enables the detection of molecular minimal residual disease
in virtually every patient, but its clinical value for the prediction of relapse has yet to be …

… Treatment of patients with acute myeloid leukemia (AML) … strong correlations of minimal
residual disease (MRD) … evaluation by MFC at diagnosis to identify leukemia-associated aberrant …

… In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease
… ALL is well demonstrated; studies in adult patients also support its prognostic value. Hence, …

… assay's ability to classify patients as high MRD (ie, when the number of leukemic blasts in a
… accuracy in defining patients with low MRD (ie, when the number of leukemic cells in a tissue …

… In this view, measure of minimal residual disease (MRD) promises to be an efficient tool to
establish on an individual basis the patient's leukemia's susceptibility to treatment, enhancing …

… residual leukemic cells in ALL patients. The advent of novel techniques, namely next
generation flow cytometry (NGF), digital-droplet-PCR (ddPCR), and next generation sequencing (…

… In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly
evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by their …

… patients, relapse is thought to result from subclinical levels of residual leukemia, termed minimal
residual disease (… rate of patients. A major goal of these studies is to be able and identify …